---
title: "Lifeward: Buy Rating Reiterated as Partner-Led Growth Strategy Drives Momentum; 12-Month Price Target Maintained at $10"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296514277.md"
description: "H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Lifeward with a $10 price target, citing partner-led growth momentum. Q2 2026 revenue rose 16% YoY to $6.6M, driven by strong U.S. sales and double-digit growth in ReWalk and AlterG lines. The Ottobock Care pilot aims to expand access via 50 clinics, supporting capital-efficient revenue streams. Despite acknowledged risks, the analyst views the risk-reward profile as attractive, supported by robust balance sheet metrics including $11.2M in growth capital."
datetime: "2026-08-20T14:55:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296514277.md)
  - [en](https://longbridge.com/en/news/296514277.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296514277.md)
generator: "portal-rs"
---

# Lifeward: Buy Rating Reiterated as Partner-Led Growth Strategy Drives Momentum; 12-Month Price Target Maintained at $10

Lifeward, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on the stock and has a $10.00 price target.

### Summer Sale - Claim 70% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Swayampakula Ramakanth has given his Buy rating due to a combination of factors related to Lifeward’s operating momentum and business model. He highlights that second-quarter 2026 revenue rose 16% year over year to $6.6M, with U.S. sales climbing 33% and both ReWalk Personal Exoskeleton and AlterG product lines showing double-digit growth, supporting his view that the new commercial strategy is starting to drive a meaningful inflection in the top line.

Ramakanth’s rating is based on the potential of Lifeward’s partner-led distribution approach and the company’s valuation upside. The Ottobock Care pilot, which expands access to ReWalk through more than 50 U.S. clinics, is seen as a capital-efficient way to build a durable revenue stream, while Lifeward’s access to up to $11.2M in growth capital and pro forma net cash of about $6.5M underpin its balance sheet. Using a risk-adjusted NPV of future revenues and net cash, he maintains a 12‑month price target of $10, viewing the risk‑reward profile as attractive despite acknowledged commercial, partnership, regulatory, financial, and IP risks.

### Related Stocks

- [LFWD.US](https://longbridge.com/en/quote/LFWD.US.md)

## Related News & Research

- [Lifeward Reports Strong Second Quarter 2026 Financial Results as Commercial Execution Drives Growth | LFWD Stock News](https://longbridge.com/en/news/295940947.md)
- [Lifeward launches pilot program with Ottobock Care to expand access to ReWalk personal exoskeleton](https://longbridge.com/en/news/294962693.md)
- [Denison Mines (DNN) Receives a Buy from Roth MKM](https://longbridge.com/en/news/296056406.md)
- [MA Financial Group Sticks to Its Buy Rating for Larvotto Resources Limited (LRV)](https://longbridge.com/en/news/296036753.md)
- [DBS Keeps Their Buy Rating on Geely Automobile Holdings (GELYF)](https://longbridge.com/en/news/296067847.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**